{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:17:50Z","timestamp":1769156270652,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was funded by the Occupational Health Research Project in Jiangsu Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Identifying novel molecular targets for castration-resistant prostate cancer (CRPC) is crucial. This study examines the expression and functional role of small nuclear ribonucleoprotein polypeptide A (SNRPA), a core component of the U1 snRNP complex, in CRPC. Bioinformatics analyses indicate a positive correlation between SNRPA overexpression and the aggressiveness of prostate cancer, with high levels linked to poor outcomes. Single-cell RNA data further shows increased SNRPA expression in prostate cancer cells. Expression of SNRPA is also elevated in both locally-treated CRPC tissues and various CRPC cells. Knockdown via shRNA or knockout using CRISPR\/Cas9 significantly reduced cellular proliferation, migration, and invasion in CRPC cells, while inducing apoptosis. SNRPA depletion decreased complex I activity, ATP production, and mitochondrial membrane potential, increased reactive oxygen species levels, and downregulated NDUFB8\/NDUFS9 expression. In contrast, SNRPA overexpression enhanced the aggressive phenotype of CRPC cells, boosting mitochondrial complex I activity and ATP generation, while upregulating NDUFB8\/NDUFS9. In vivo studies using xenograft models further validated the therapeutic potential of targeting SNRPA. SNRPA knockdown significantly inhibited CRPC xenograft growth, reduced ATP levels, and altered redox balance, as evidenced by decreased glutathione\/glutathione disulfide ratio and increased lipid peroxidation. These effects were accompanied by decreased proliferation, increased apoptosis and downregulated NDUFB8\/NDUFS9. Our findings collectively suggest that SNRPA plays a crucial role in driving CRPC progression and represents a promising therapeutic target.<\/jats:p>","DOI":"10.1038\/s41419-025-08302-8","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T08:23:58Z","timestamp":1765095838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SNRPA upregulation promotes mitochondrial function and drives CRPC aggressiveness"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7136-4299","authenticated-orcid":false,"given":"Xiao-long","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-4833","authenticated-orcid":false,"given":"Yong-qiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8280-2196","authenticated-orcid":false,"given":"Mei-hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-3823","authenticated-orcid":false,"given":"Bo-xin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"8302_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8302_CR2","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"8302_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0457-6","volume":"13","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015;13:206.","journal-title":"BMC Med"},{"key":"8302_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrurol.2013.137","volume":"10","author":"M Bishr","year":"2013","unstructured":"Bishr M, Saad F. Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol. 2013;10:522\u20138.","journal-title":"Nat Rev Urol"},{"key":"8302_CR5","doi-asserted-by":"publisher","first-page":"327253","DOI":"10.1155\/2012\/327253","volume":"2012","author":"TM Amaral","year":"2012","unstructured":"Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer. 2012;2012:327253.","journal-title":"Prostate Cancer"},{"key":"8302_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/wrna.1257","volume":"6","author":"J Guiro","year":"2015","unstructured":"Guiro J, O\u2019Reilly D. Insights into the U1 small nuclear ribonucleoprotein complex superfamily. Wiley Interdiscip Rev RNA. 2015;6:79\u201392.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"8302_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/348515a0","volume":"348","author":"K Nagai","year":"1990","unstructured":"Nagai K, Oubridge C, Jessen TH, Li J, Evans PR. Crystal structure of the RNA-binding domain of the U1 small nuclear ribonucleoprotein A. Nature. 1990;348:515\u201320.","journal-title":"Nature"},{"key":"8302_CR8","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1126\/science.2933810","volume":"230","author":"B Chabot","year":"1985","unstructured":"Chabot B, Black DL, LeMaster DM, Steitz JA. The 3\u2019 splice site of pre-messenger RNA is recognized by a small nuclear ribonucleoprotein. Science. 1985;230:1344\u20139.","journal-title":"Science"},{"key":"8302_CR9","doi-asserted-by":"publisher","first-page":"842069","DOI":"10.3389\/fimmu.2022.842069","volume":"13","author":"A Jiang","year":"2022","unstructured":"Jiang A, Meng J, Gong W, Zhang Z, Gan X, Wang J, et al. Elevated SNRPA1, as a promising predictor reflecting severe clinical outcome via effecting tumor immunity for ccRCC, is related to cell invasion, metastasis, and sunitinib sensitivity. Front Immunol. 2022;13:842069.","journal-title":"Front Immunol"},{"key":"8302_CR10","doi-asserted-by":"publisher","first-page":"109076","DOI":"10.1016\/j.biopha.2019.109076","volume":"117","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Lei F, Chang Y, Gao Z, Wang Y, Gao Q, et al. An oncogenic gene, SNRPA1, regulates PIK3R1, VEGFC, MKI67, CDK1 and other genes in colorectal cancer. Biomed Pharmacother. 2019;117:109076.","journal-title":"Biomed Pharmacother"},{"key":"8302_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12484","volume":"51","author":"N Dou","year":"2018","unstructured":"Dou N, Yang D, Yu S, Wu B, Gao Y, Li Y. SNRPA enhances tumour cell growth in gastric cancer through modulating NGF expression. Cell Prolif. 2018;51:e12484.","journal-title":"Cell Prolif"},{"key":"8302_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05606-5","volume":"14","author":"YY Mi","year":"2023","unstructured":"Mi YY, Ji Y, Zhang L, Sun CY, Wei BB, Yang DJ, et al. A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo. Cell Death Dis. 2023;14:67.","journal-title":"Cell Death Dis"},{"key":"8302_CR13","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.7150\/ijbs.77126","volume":"18","author":"J Zhang","year":"2022","unstructured":"Zhang J, Yin DP, Zhang Y, Zhang JN, Yang Y, Zhang ZQ, et al. Identification of Galphai3 as a novel molecular therapeutic target of cervical cancer. Int J Biol Sci. 2022;18:5667\u201380.","journal-title":"Int J Biol Sci"},{"key":"8302_CR14","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.7150\/ijbs.68861","volume":"18","author":"ZJ Bian","year":"2022","unstructured":"Bian ZJ, Shan HJ, Zhu YR, Shi C, Chen MB, Huang YM, et al. Identification of Galphai3 as a promising target for osteosarcoma treatment. Int J Biol Sci. 2022;18:1508\u201320.","journal-title":"Int J Biol Sci"},{"key":"8302_CR15","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.7150\/thno.55655","volume":"11","author":"YY Gao","year":"2021","unstructured":"Gao YY, Ling ZY, Zhu YR, Shi C, Wang Y, Zhang XY, et al. The histone acetyltransferase HBO1 functions as a novel oncogenic gene in osteosarcoma. Theranostics. 2021;11:4599\u2013615.","journal-title":"Theranostics"},{"key":"8302_CR16","doi-asserted-by":"crossref","unstructured":"Gabr, SA, Elsaed, WM, Eladl, MA, El-Sherbiny, M, Ebrahim, HA, Asseri, SM, et al. Curcumin modulates oxidative stress, fibrosis, and apoptosis in drug-resistant cancer cell lines. Life (Basel). 2022;12:1427.","DOI":"10.3390\/life12091427"},{"key":"8302_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"},{"key":"8302_CR18","doi-asserted-by":"crossref","unstructured":"Schaaf ZA, Ning S, Leslie AR, Sharifi M, Han X, Armstrong C, et al. Therapeutic resistance models and treatment sequencing in advanced prostate cancer. Cancers (Basel). 2023;15;5273.","DOI":"10.3390\/cancers15215273"},{"key":"8302_CR19","doi-asserted-by":"publisher","first-page":"873876","DOI":"10.3389\/fonc.2022.873876","volume":"12","author":"P Kong","year":"2022","unstructured":"Kong P, Zhang L, Zhang Z, Feng K, Sang Y, Duan X, et al. Emerging proteins in CRPC: functional roles and clinical implications. Front Oncol. 2022;12:873876.","journal-title":"Front Oncol"},{"key":"8302_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ejca.2013.12.004","volume":"50","author":"D Lorente","year":"2014","unstructured":"Lorente D, De Bono JS. Molecular alterations and emerging targets in castration resistant prostate cancer. Eur J Cancer. 2014;50:753\u201364.","journal-title":"Eur J Cancer"},{"key":"8302_CR21","doi-asserted-by":"crossref","unstructured":"Chen CL, Lin CY, Kung HJ. Targeting mitochondrial OXPHOS and their regulatory signals in prostate cancers. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms222413435"},{"key":"8302_CR22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/1873-3468.13995","volume":"595","author":"E Fernandez-Vizarra","year":"2021","unstructured":"Fernandez-Vizarra E, Zeviani M. Mitochondrial disorders of the OXPHOS system. FEBS Lett. 2021;595:1062\u2013106.","journal-title":"FEBS Lett"},{"key":"8302_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.mito.2012.07.106","volume":"12","author":"SJ Hoefs","year":"2012","unstructured":"Hoefs SJ, Rodenburg RJ, Smeitink JA, van den Heuvel LP. Molecular base of biochemical complex I deficiency. Mitochondrion. 2012;12:520\u201332.","journal-title":"Mitochondrion"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08302-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08302-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08302-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:18:05Z","timestamp":1769098685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08302-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8302"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08302-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human tissue and cells were conducted with ethical approval from the Second Affiliated Hospital of Soochow University\u2019s Ethics Committee, adhering to the principles outlined in the Declaration of Helsinki. Written-informed consent was obtained from all participants. The animal studies adhered to the guidelines set forth by the Institutional Animal Care and Use Committee (IACUC) and received ethical approval from the Ethics Review Board of the Second Affiliated Hospital of Soochow University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"74"}}